Raymond James Financial
CLRB icon

Raymond James Financial’s Cellectar Biosciences CLRB Stock Holding History

Raymond James Financial’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-133
Closed -$946 – 5304
2025
Q2 		$946 Buy
+133
New +$1.16K ﹤0.01% 6575

Other funds holding CLRB

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial's CLRB Position: Q3 2025 in Review

Raymond James Financial sold out of Cellectar Biosciences (CLRB) in Q3 2025, closing a stake of 133 shares — an estimated $946 sold.

Raymond James Financial first reported a position in CLRB in Q2 2025 and held it in 1 quarter. The position peaked at $946 in Q2 2025. 21 funds tracked by Wall St. Rank hold CLRB as of Q3 2025.

  • Raymond James Financial reported no remaining Cellectar Biosciences position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 133 Cellectar Biosciences shares in Q3 2025, an estimated $946.
  • Raymond James Financial first reported a position in Cellectar Biosciences in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Cellectar Biosciences position peaked at $946 in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.